NICE Final Appraisal Favors Cost-Effectiveness Of Aromatase Inhibitors
This article was originally published in The Pink Sheet Daily
The U.K's National Institute for Health & Clinical Excellence released a final appraisal determination Aug. 11 supporting the clinical benefit of aromatase inhibitors over tamoxifen in primary adjuvant and unplanned switch treatment of early-stage breast cancer
You may also be interested in...
Although an overall survival advantage has not been shown, the U.K. agency recommends coverage of Arimidex, Aromasin and Femara.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.